COVID-19 vaccine breakthrough case investigation : information for state and local health departments

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  Objective: Investigate SARS-CoV-2 infections among people who received COVID-19 vaccine to identify trends or clustering in demographics, the administered vaccine, or the infecting virus.
  
  Case definition: A person who has SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after they completed the primary series of an FDA-authorized COVID-19 vaccine.
  
  Exclusion criteria: The person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected <45 days before the most recent positive test.
  
  Publication date from document properties.
  
  Information-for-State-and-Local-Health-Departments-COVID-19-vaccine-breakthrough-case-investigation.pdf
  
  
• Subjects:
  Case Definition Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Population Surveillance Vaccination
• Document Type:
  Pamphlet (or booklet)
• Genre:
  Fact Sheet
• Place as Subject:
  United States
• Pages in Document:
  2 unnumbered pages
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha-512:075e978bcc89d1579f6af0642bad958e24c6ca468ac4bf9fe44e85872925cc1a400c9aeb1cd9ce972c9a1a7037d1ff24aaba9d5a3a1664d61ac3b36565e109c0
• Download URL:
  https://stacks.cdc.gov/view/cdc/105216/cdc_105216_DS1.pdf
• File Type:
  [PDF - 136.71 KB ]